Search
Feed aggregator
Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss
Novo Ends Phase III Kidney Disease Trial, Incurs More Than $800M Q2 Impairment Loss 6/27/2024
AbbVie, Genmab Secure FDA Label Expansion for Epkinly in Follicular Lymphoma
AbbVie, Genmab Secure FDA Label Expansion for Epkinly in Follicular Lymphoma 6/27/2024
CDC Narrows RSV Vaccine Recommendations for Seniors
CDC Narrows RSV Vaccine Recommendations for Seniors 6/27/2024
New Team, Same Company: How to Transition to Your New Role
New Team, Same Company: How to Transition to Your New Role 6/27/2024
Leadership Lab: 3 Strategies for an Executive’s Discreet Job Search
Leadership Lab: 3 Strategies for an Executive’s Discreet Job Search 6/27/2024
5 Top Companies Hiring in the Washington, D.C., Area
5 Top Companies Hiring in the Washington, D.C., Area 6/27/2024
Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate
Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate 6/26/2024
Zealand to Raise $1B in Public Offering to Fund Obesity Candidates
Zealand to Raise $1B in Public Offering to Fund Obesity Candidates 6/26/2024
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic 6/26/2024
Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria
Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria 6/26/2024
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval
Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval 6/26/2024
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade
Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade 6/26/2024
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs
How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs 6/26/2024
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights 6/26/2024
After Full Approval, Sarepta Lays Out Its Next Moves
After Full Approval, Sarepta Lays Out Its Next Moves 6/26/2024
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good
Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good 6/26/2024
5 FDA Decisions to Watch in the Second Half of 2024
5 FDA Decisions to Watch in the Second Half of 2024 6/24/2024
FDA Action Alert: Merck, Verona, AbbVie and Rocket
FDA Action Alert: Merck, Verona, AbbVie and Rocket 6/24/2024
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients 6/21/2024
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative
Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative 6/21/2024
World Pharma News
- AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors
- Researchers identify natural compound that disarms drug-resistant bacteria
- Scientists discover a new way to make drug-resistant cancer treatable again
- A new drug concept to treat obesity and type 2 diabetes
- Autonomous AI-based drug prescribing rife with potential problems